Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study

Mitsuhiro Iwahashi, Hiroshi Inoue, Tsukasa Matsubara, Takaaki Tanaka, Koichi Amano, Toshihisa Kanamono, Teruaki Nakano, Shoichi Uchimura, Tomomaro Izumihara, Akira Yamazaki, Chetan S. Karyekar, Tsutomu Takeuchi

研究成果: Article

11 引用 (Scopus)

抄録

OBJECTIVE: To evaluate efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept and background methotrexate (MTX) in Japanese patients with rheumatoid arthritis (RA) and inadequate response to MTX (MTX-IR).

METHODS: Double-dummy, double-blind study (NCT01001832); 118 adults with ≥ 10 swollen joints, ≥ 12 tender joints and C-reactive protein (CRP) ≥ 0.8 mg/dL randomized 1:1 to SC abatacept (125 mg weekly) with IV loading (∼10 mg/kg on Day 1), or IV abatacept (∼10 mg/kg monthly) for 169 days, both also receiving MTX (6-8 mg/week). Primary endpoint was Day 169 American College of Rheumatology (ACR)20 response; other efficacy endpoints, safety and immunogenicity were assessed.

RESULTS: Similar proportions of patients achieved ACR20 responses at Day 169 with SC (91.5% [95% CI 81.3, 97.2]) and IV abatacept (83.1% [71.0, 91.6]). ACR50/70 responses, adjusted mean changes from baseline in Health Assessment Questionnaire-Disability Index scores and remission rates (28-joint Disease Activity Score [CRP] <2.6) were also comparable between groups. Serious adverse event frequencies (5.1% vs. 3.4%) were similar with both formulations. One patient per group tested seropositive for immunogenicity. Weekly SC abatacept dosing achieved mean serum concentrations > 10 μg/mL (minimum therapeutic target).

CONCLUSIONS: SC abatacept demonstrated comparable efficacy and safety to IV abatacept, with low immunogenicity rates, in MTX-IR Japanese patients with RA.

元の言語English
ページ(範囲)885-891
ページ数7
ジャーナルModern rheumatology / the Japan Rheumatism Association
24
発行部数6
DOI
出版物ステータスPublished - 2014 11 1

Fingerprint

Methotrexate
Rheumatoid Arthritis
Pharmacokinetics
Safety
C-Reactive Protein
Joints
Joint Diseases
Double-Blind Method
Abatacept
Health

ASJC Scopus subject areas

  • Medicine(all)

これを引用

Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate : a Phase II/III, randomized study. / Iwahashi, Mitsuhiro; Inoue, Hiroshi; Matsubara, Tsukasa; Tanaka, Takaaki; Amano, Koichi; Kanamono, Toshihisa; Nakano, Teruaki; Uchimura, Shoichi; Izumihara, Tomomaro; Yamazaki, Akira; Karyekar, Chetan S.; Takeuchi, Tsutomu.

:: Modern rheumatology / the Japan Rheumatism Association, 巻 24, 番号 6, 01.11.2014, p. 885-891.

研究成果: Article

Iwahashi, Mitsuhiro ; Inoue, Hiroshi ; Matsubara, Tsukasa ; Tanaka, Takaaki ; Amano, Koichi ; Kanamono, Toshihisa ; Nakano, Teruaki ; Uchimura, Shoichi ; Izumihara, Tomomaro ; Yamazaki, Akira ; Karyekar, Chetan S. ; Takeuchi, Tsutomu. / Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate : a Phase II/III, randomized study. :: Modern rheumatology / the Japan Rheumatism Association. 2014 ; 巻 24, 番号 6. pp. 885-891.
@article{5fd6c7740f6c4f76b3e788938b02e775,
title = "Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study",
abstract = "OBJECTIVE: To evaluate efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept and background methotrexate (MTX) in Japanese patients with rheumatoid arthritis (RA) and inadequate response to MTX (MTX-IR).METHODS: Double-dummy, double-blind study (NCT01001832); 118 adults with ≥ 10 swollen joints, ≥ 12 tender joints and C-reactive protein (CRP) ≥ 0.8 mg/dL randomized 1:1 to SC abatacept (125 mg weekly) with IV loading (∼10 mg/kg on Day 1), or IV abatacept (∼10 mg/kg monthly) for 169 days, both also receiving MTX (6-8 mg/week). Primary endpoint was Day 169 American College of Rheumatology (ACR)20 response; other efficacy endpoints, safety and immunogenicity were assessed.RESULTS: Similar proportions of patients achieved ACR20 responses at Day 169 with SC (91.5{\%} [95{\%} CI 81.3, 97.2]) and IV abatacept (83.1{\%} [71.0, 91.6]). ACR50/70 responses, adjusted mean changes from baseline in Health Assessment Questionnaire-Disability Index scores and remission rates (28-joint Disease Activity Score [CRP] <2.6) were also comparable between groups. Serious adverse event frequencies (5.1{\%} vs. 3.4{\%}) were similar with both formulations. One patient per group tested seropositive for immunogenicity. Weekly SC abatacept dosing achieved mean serum concentrations > 10 μg/mL (minimum therapeutic target).CONCLUSIONS: SC abatacept demonstrated comparable efficacy and safety to IV abatacept, with low immunogenicity rates, in MTX-IR Japanese patients with RA.",
keywords = "Abatacept, Intravenous infusion, Japan, Rheumatoid arthritis, Subcutaneous injection",
author = "Mitsuhiro Iwahashi and Hiroshi Inoue and Tsukasa Matsubara and Takaaki Tanaka and Koichi Amano and Toshihisa Kanamono and Teruaki Nakano and Shoichi Uchimura and Tomomaro Izumihara and Akira Yamazaki and Karyekar, {Chetan S.} and Tsutomu Takeuchi",
year = "2014",
month = "11",
day = "1",
doi = "10.3109/14397595.2014.881954",
language = "English",
volume = "24",
pages = "885--891",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate

T2 - a Phase II/III, randomized study

AU - Iwahashi, Mitsuhiro

AU - Inoue, Hiroshi

AU - Matsubara, Tsukasa

AU - Tanaka, Takaaki

AU - Amano, Koichi

AU - Kanamono, Toshihisa

AU - Nakano, Teruaki

AU - Uchimura, Shoichi

AU - Izumihara, Tomomaro

AU - Yamazaki, Akira

AU - Karyekar, Chetan S.

AU - Takeuchi, Tsutomu

PY - 2014/11/1

Y1 - 2014/11/1

N2 - OBJECTIVE: To evaluate efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept and background methotrexate (MTX) in Japanese patients with rheumatoid arthritis (RA) and inadequate response to MTX (MTX-IR).METHODS: Double-dummy, double-blind study (NCT01001832); 118 adults with ≥ 10 swollen joints, ≥ 12 tender joints and C-reactive protein (CRP) ≥ 0.8 mg/dL randomized 1:1 to SC abatacept (125 mg weekly) with IV loading (∼10 mg/kg on Day 1), or IV abatacept (∼10 mg/kg monthly) for 169 days, both also receiving MTX (6-8 mg/week). Primary endpoint was Day 169 American College of Rheumatology (ACR)20 response; other efficacy endpoints, safety and immunogenicity were assessed.RESULTS: Similar proportions of patients achieved ACR20 responses at Day 169 with SC (91.5% [95% CI 81.3, 97.2]) and IV abatacept (83.1% [71.0, 91.6]). ACR50/70 responses, adjusted mean changes from baseline in Health Assessment Questionnaire-Disability Index scores and remission rates (28-joint Disease Activity Score [CRP] <2.6) were also comparable between groups. Serious adverse event frequencies (5.1% vs. 3.4%) were similar with both formulations. One patient per group tested seropositive for immunogenicity. Weekly SC abatacept dosing achieved mean serum concentrations > 10 μg/mL (minimum therapeutic target).CONCLUSIONS: SC abatacept demonstrated comparable efficacy and safety to IV abatacept, with low immunogenicity rates, in MTX-IR Japanese patients with RA.

AB - OBJECTIVE: To evaluate efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept and background methotrexate (MTX) in Japanese patients with rheumatoid arthritis (RA) and inadequate response to MTX (MTX-IR).METHODS: Double-dummy, double-blind study (NCT01001832); 118 adults with ≥ 10 swollen joints, ≥ 12 tender joints and C-reactive protein (CRP) ≥ 0.8 mg/dL randomized 1:1 to SC abatacept (125 mg weekly) with IV loading (∼10 mg/kg on Day 1), or IV abatacept (∼10 mg/kg monthly) for 169 days, both also receiving MTX (6-8 mg/week). Primary endpoint was Day 169 American College of Rheumatology (ACR)20 response; other efficacy endpoints, safety and immunogenicity were assessed.RESULTS: Similar proportions of patients achieved ACR20 responses at Day 169 with SC (91.5% [95% CI 81.3, 97.2]) and IV abatacept (83.1% [71.0, 91.6]). ACR50/70 responses, adjusted mean changes from baseline in Health Assessment Questionnaire-Disability Index scores and remission rates (28-joint Disease Activity Score [CRP] <2.6) were also comparable between groups. Serious adverse event frequencies (5.1% vs. 3.4%) were similar with both formulations. One patient per group tested seropositive for immunogenicity. Weekly SC abatacept dosing achieved mean serum concentrations > 10 μg/mL (minimum therapeutic target).CONCLUSIONS: SC abatacept demonstrated comparable efficacy and safety to IV abatacept, with low immunogenicity rates, in MTX-IR Japanese patients with RA.

KW - Abatacept

KW - Intravenous infusion

KW - Japan

KW - Rheumatoid arthritis

KW - Subcutaneous injection

UR - http://www.scopus.com/inward/record.url?scp=84932122801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932122801&partnerID=8YFLogxK

U2 - 10.3109/14397595.2014.881954

DO - 10.3109/14397595.2014.881954

M3 - Article

C2 - 24708204

AN - SCOPUS:84932122801

VL - 24

SP - 885

EP - 891

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 6

ER -